Lonsurf (trifluridine/tipiracil) / Otsuka 
Welcome,         Profile    Billing    Logout  
 6 Diseases   125 Trials   125 Trials   2571 News 


«12...2122232425262728293031...3334»
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, fluorouracil / Generic mfg., irinotecan / Generic mfg.
    Journal:  Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. (Pubmed Central) -  Jul 16, 2020   
    Trifluridine/tipiracil is available on the Australian Pharmaceutical Benefits Scheme for the treatment of patients with metastatic colorectal cancer (mCRC) previously treated with, or not considered candidates for, fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents and anti-epidermal growth factor receptor agents...Whereas the primary mechanism of action of fluoropyrimidines such as fluorouracil (5-FU) and capecitabine is enzyme inhibition of nucleotide synthesis, trifluridine/tipiracil primarily acts by incorporation into DNA, resulting in DNA dysfunction...Trifluridine/tipiracil therapy benefits appropriately selected patients who have an ECOG performance status of 0 or 1, with no more than mild hepatic impairment or mild-to-moderate renal impairment, and who are capable of adhering to oral therapy safely. Appropriate dosing, monitoring for adverse events and effective management of side effects are essential.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, TAS / 102
    Journal:  TAS-102 plus bevacizumab in metastatic colorectal cancer. (Pubmed Central) -  Jul 16, 2020   
    Appropriate dosing, monitoring for adverse events and effective management of side effects are essential. No abstract available
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Enrollment open:  LONGBOARD: LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy (clinicaltrials.gov) -  Jul 13, 2020   
    P2,  N=250, Recruiting, 
    Combining bevacizumab with FTD/TPI improves the survival outcomes with manageable toxicity, regardless of the usage history of bevacizumab in front-line treatment, in patients with mCRC. Not yet recruiting --> Recruiting
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
    Review, Journal:  Metastatic colorectal cancer: therapeutic options for treating refractory disease. (Pubmed Central) -  Jul 2, 2020   
    However, the limited clinical efficacy of those treatments underscores the need for ongoing development of systemic therapy options for this unique cohort of patients. Here, we review the current and emerging treatment landscape for chemorefractory mcrc.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
    Clinical, Journal:  Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients. (Pubmed Central) -  Jun 11, 2020   
    In conclusion, we underline the efficacy of trifluridine/tipiracil and regorafenib in the real-life setting. We describe predictive adverse events like neutropenia/leukopenia, which might be used as surrogate marker in anticancer therapy beyond second line treatment.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Metastases:  TACTIC: A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer (clinicaltrials.gov) -  Jun 11, 2020   
    P2,  N=0, Withdrawn, 
    We describe predictive adverse events like neutropenia/leukopenia, which might be used as surrogate marker in anticancer therapy beyond second line treatment. N=52 --> 0 | Trial completion date: Feb 2024 --> Jun 2020 | Not yet recruiting --> Withdrawn | Trial primary completion date: Feb 2023 --> Jun 2020
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
    Journal:  Trifluridine/Tipiracil for the Treatment of Metastatic Gastric Cancer. (Pubmed Central) -  May 28, 2020   
    Detail of the phase III TAGS trial are discussed in this review.Expert Opinion: Trifluridine/tipiracil after at least two previous courses of systemic chemotherapy improved rates of survival of gastric cancer; thus it has become one of treatment options in affected patients. Currently, several clinical trials of trifluridine/tipiracil in combination with other anticancer agents such as ramucirumab (an anti-vascular endothelial growth factor receptor 2 monoclonal antibody) for patients with AGC are ongoing.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion, PD(L)-1 Biomarker, IO biomarker:  LUPIN: Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer (clinicaltrials.gov) -  May 27, 2020   
    P1,  N=78, Completed, 
    Currently, several clinical trials of trifluridine/tipiracil in combination with other anticancer agents such as ramucirumab (an anti-vascular endothelial growth factor receptor 2 monoclonal antibody) for patients with AGC are ongoing. Active, not recruiting --> Completed
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) (clinicaltrials.gov) -  May 26, 2020   
    P1,  N=18, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Review, Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO Biomarker:  Treatment sequencing in metastatic colorectal cancer. (Pubmed Central) -  May 23, 2020   
    Immunotherapy with pembrolizumab or nivolumab ± ipilimumab may be considered for patients with high microsatellite instability disease...Ongoing trials are investigating the optimal sequencing and timing of therapies for mCRC. Molecular profiling has established new targets, and increasing knowledge of tumour evolution under drug pressure will possibly impact on sequencing.
  • ||||||||||  CA-102N / Holy Stone Healthcare
    CA102N suppresses the growth of mouse colon cancer by inhibition of PI3K pathway and immune modulation (Virtual Meeting II: E-Posters) -  May 16, 2020 - Abstract #AACRII2020AACR-II_4033;    
    Additionally, the protein expression of pAkt and pS6 in CA102N (200 mg/kg) treated tumor tissues were significantly down-regulated by more than 50% compared to that of control group, while CA102N (50 mg/kg) treatment only slightly altered the abundance of these proteins, suggesting antitumor activity of CA102N in different doses can potentially be mediated by differential mechanisms. Together, these findings suggest that the lower dose of CA102N exerts antitumor activity in mouse colon tumor model by immune modulation whereas the antitumor activity of the higher dose of CA102N might be mediated through inhibition of PI3kinase pathway on tumor tissues.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
    Continuous trifluridine treatment in colorectal cancer cell lines- investigating its potential (Virtual Meeting II: E-Posters) -  May 16, 2020 - Abstract #AACRII2020AACR-II_3899;    
    Therefore, FTD is expected to be effective even after treatment with standard chemotherapy. Although FTD/TPI is currently used in the later line, it is suggested from this basic study that FTD/TPI may be applicable to take to the front line therapy.
  • ||||||||||  SAR408701 / Sanofi, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Preclinical efficacy data for the anti-CEACAM5-DM4 ADC SAR408701 supports further development in lung and gastro-intestinal cancers (Virtual Meeting II: E-Posters) -  May 16, 2020 - Abstract #AACRII2020AACR-II_1860;    
    These results suggest that SAR408701 can be advantageously combined with SoC in gastro-intestinal (GI) cancers.In summary, preclinical data show that SAR408701 displays a strong antitumor activity as a single agent in NSCLC and in combination with SOC in GI cancers, supporting further development in these indications. Furthermore, SAR408701 could be a potential good candidate to be combined with ICIs in NSCLC.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, irinotecan / Generic mfg.
    [VIRTUAL] Clinical impact of oral intake in third-line treatment for advanced gastric cancer () -  May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_306;    
    Background Trifluridine/tipiracil, an oral drug, was approved in Japan for patients with advanced gastric cancer (AGC) according to the TAGS trial...Among these INSUF patients, only 2 patients (5%) achieved IMP (nivolumab 1 patient; irinotecan 1 patient)...Legal entity responsible for the study The author. Funding Has not received any funding.